Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

Novo Nordisk continues to build a case for its oral semaglutide GLP ... blood sugar and weight in kidney-impaired patients with type 2 disease. The 26-week PIONEER 5 trial is one of 10 clinical ...

Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial1.Data ...

Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

Trial confirms that oral semaglutide lowers cardiovascular risk in type 2 diabetes, regardless of SGLT2i use. Read more!

Novo Nordisk’s SOUL trial confirms that oral semaglutide significantly reduces the risk of heart attack, stroke, and ...

Semaglutide ... obesity, kidney disease, cardiovascular disease including atherosclerotic vascular disease and heart failure. In the trial called STRIDE, 792 people with type 2 diabetes and ...

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. | Eli Lilly has met its goal of ...